TITLE

Cervical Cancer Update

PUB. DATE
October 2007
SOURCE
PharmaWatch: Cancer;Oct2007, Vol. 6 Issue 10, p8
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports that Nventa Biopharmaceuticals Corp. has started a Phase I trial which evaluates the safeness and tolerability of its therapeutic vaccine in patients with cervical intraepithelial neoplasia (CIN) in the U.S. It also aims to assess T-cell and B-cell specific HPV-E7 immune responses. Peter Emtage, vice president of research and development (R&D) at Nventa, believes that the trial would produce invaluable data of new HspE7 for use in designing future efficacy trials.
ACCESSION #
26926508

 

Related Articles

  • Nventa reports positive results from Phase I cervical dysplasia trial.  // PharmaWatch: Cancer;Sep2008, Vol. 7 Issue 9, p11 

    The article reports on the result of the drug study conducted by Nventa Biopharmaceuticals Corp. which assesses the effectiveness of its HspE7 drug for treating cervical intraepithelial neoplasia (CIN) patients. The study focused on evaluating the drug's response and immunogenecity to different...

  • Research Update.  // PharmaWatch: Biotechnology;Oct2007, Vol. 6 Issue 10, p4 

    The article offers news briefs related to medical research. Sinovac Biotech Ltd. started its move to immunize volunteers for pandemic avian influenza vaccine trial. Thallion Pharmaceuticals Inc. has completed its clinical trial with ECO-4601 as part of the phase II extention for cancer drug...

  • Cervarix comes out ahead of Gardasil in trial.  // Pulse;5/13/2009, Vol. 69 Issue 16, p2 

    The article reports on the result of the first head-to-head clinical trial of the cervical cancer vaccines Cervarix and Gardasil. The clinical trial found that Cervarix is more effective than Gardasil and elicits stronger immune response in women. The clinical trial also assessed the capability...

  • Cervical Cancer Update.  // PharmaWatch: Cancer;Sep2007, Vol. 6 Issue 9, p10 

    The article offers information related to cervical cancer. According to Merck & Co. Inc., two of its vaccines will be used in a U.S. immunization program for children. According to GlaxoSmithKline, its cervical cancer candidate vaccine, has received a positive opinion from a European advisory...

  • CLINIC ROUNDUP.  // BioWorld Today;3/27/2008, Vol. 19 Issue 60, p2 

    This section offers news briefs related to the biotechnology industry. Metabolex Inc. announced that it has dosed the first cohort of healthy subjects in a Phase I clinical trial of MBX-2982, a potential treatment for Type II diabetes. Nventa Biopharmaceuticals Corp. revealed interim...

  • NVENTA UNVEILS IMMUNOLOGICAL DATA FROM HSPE7 PHASE 1 TRIAL.  // Worldwide Biotech;May2008, Vol. 20 Issue 5, p1 

    The article reports on the release of interim immunological data from the first two cohorts of Nventa Biopharmaceuticals Corporation's ongoing Phase 1 clinical trial of its lead product candidate, HspE7. The product is being tested in patients with cervical intraepithelial neoplasia (CIN). It...

  • Cervical cancer breakthrough.  // European Pharmaceutical Executive;Nov/Dec2005, p12 

    The article reports that an investigational vaccine from Merck & Co. Inc. has been shown to be 100 percent effective against two virus strains which cause the most incidences of cervical cancer. The phase III trial found that Gardasil prevents high-grade cervical pre-cancers and non-invasive...

  • HPV 16/18 PROPHYLACTIC CERVICAL CANCER VACCINE: DEVELOPMENT UPDATE. Bock, Hans // Infectious Diseases in Obstetrics & Gynecology;2006, Vol. 2006, p13 

    Rationale for development. HPV types 16 and 18 are most frequently associated with cervical cancer, occurring in > 70% cases globally [72]. In some locations (the Philippines, Costa Rica, Bangkok), the odds ratio associating HPV and cervical cancer is > 10 times that of cigarette smoking and...

  • Correction: Intent to Participate in Future Cervical Cancer Screenings Is Lower when Satisfaction with the Decision to Be Vaccinated Is Neutral.  // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics